If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-30. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
== Structure of penicillin binding protein 3 == Penicillin binding protein 3 is important for bacteria wall synthesis and is a main target in β-lactam antibiotics. It is a two-domain protein containing a C-terminal transpeptidase linked to an extended N-terminal domain. This protein is similar to other class B PBP’s since it contains an α-helical subdomain or “head” domain towards the N-terminus. The N-terminal domain’s function is still not known but it is thought it serves to position the transpeptidase domain away from the inner membrane as part of a multienzyme complex involved in cell wall biosynthesis.
==== Weight training and other types of physical activity cause baldness ==== Because it increases testosterone levels, many Internet forums have put forward the idea that weight training and other forms of exercise increase hair loss in predisposed individuals. Although scientific studies do support a correlation between exercise and testosterone, no direct study has found a link between exercise and baldness. However, a few have found a relationship between a sedentary life and baldness, suggesting exercise is causally relevant. The type or quantity of exercise may influence hair loss. Testosterone levels are not a good marker of baldness, and many studies actually show paradoxical low testosterone in balding persons, although research on the implications is limited.
=== EC 1.21.3 With oxygen as acceptor === EC 1.21.3.1: isopenicillin-N synthase EC 1.21.3.2: columbamine oxidase EC 1.21.3.3: reticuline oxidase EC 1.21.3.4: sulochrin oxidase ((+)-bisdechlorogeodin-forming) EC 1.21.3.5: sulochrin oxidase ((-)-bisdechlorogeodin-forming) EC 1.21.3.6: aureusidin synthase EC 1.21.3.7: tetrahydrocannabinolic acid synthase EC 1.21.3.8: cannabidiolic acid synthase EC 1.21.3.9: now classified as EC 1.21.98.2, dichlorochromopyrrolate synthase
In March 2013, Carrey announced that he had written a children's book titled How Roland Rolls, about a scared wave named Roland. He described it as "kind of a metaphysical children's story, which deals with a lot of heavy stuff in a really childish way." Carrey self-published the book, which was released in September 2013. On March 25, 2013, Carrey released a parody music video with Eels through Funny or Die, with Carrey replacing Mark Oliver Everett on vocals. The song and video, titled "Cold Dead Hand" and set as a musical act during the variety program Hee Haw, lampoons American gun culture, and specifically former NRA spokesperson Charlton Heston. Carrey delivered the commencement address at Maharishi University of Management in Fairfield, Iowa, in May 2014 and received an honorary doctorate for his achievements as a comedian, artist, author, and philanthropist. On August 29, 2014, Carrey was honored by Canada Post with a limited-edition postage stamp with his portrait on it. Carrey was a producer on Rubble Kings, a 2015 documentary film that depicts events preceding and following the Hoe Avenue peace meeting. In June 2017, Showtime began airing the dramedy I'm Dying Up Here, for which Carrey served as the executive producer. The show, which chronicles a group of stand-up comics in 1970s Los Angeles, incorporates aspects of Carrey's own experience. In September of that year, that same network announced that he would star in a comedy series titled Kidding, which would reunite Carrey and director Michel Gondry.
Sorenson, MD, from the Mayo Clinic in Rochester, Minnesota "While this is very disappointing, at least it was definitive and gives, I think, a pretty definitive answer, at least for this strategy for this drug," Dr. Sorenson said. However, he added, "there is still a great deal of evidence that the IGF-1 pathway can be beneficial to people who have ALS, but just not the way we administered it." Novel methods of delivering IGF-1 in a more selected fashion are now under way, including the use of viral mediators or stem cells. Two previous phase 3 trials of IGF-1 in ALS showed inconsistent results: 1 trial, carried out in North America, did find a benefit, whereas the other, a European trial, did not confirm the earlier findings. "The results of our study most resemble those of the previous European study, with no benefit in either survival or functional scales", De Sorenson concludes. "It is disappointing that we were unable to confirm the benefit that was noted in the previous North American study." Conclusive evidence points, what Iplex (and any form of IGF-1) can't slow progression in human ALS. Lot of sites that have published articles about the link between Lyme disease and ALS are sponsored by clinics specializing in the treatment of chronic Lyme disease, or by the sellers of products for treating this, or both.
Sources: en.wikipedia.org
International Union of Biochemistry and Molecular Biology (IUBMB) An international non-governmental organization devoted to promoting scientific research and education in the disciplines of biochemistry and molecular biology, primarily by standardizing biochemical nomenclature, developing and publishing laboratory methods, and awarding grants and fellowships to students and researchers.
With the antiwar movement in decline by 1972, Nixon believed his chances of reelection were good, but Kissinger kept complaining that he was losing "negotiating assets" in his talks with Tho every time a withdrawal of American forces was announced. Likewise, Kissinger noted that the major reason why Congress, despite the antiwar feelings of many of its members, kept voting to fund the war was because of the argument that it was patriotic to support "our boys in the field"; as more Americans were pulled out, Congress was less inclined to vote to fund keeping South Vietnamese "boys in the field". However, the imperatives of being re-elected were far more important to Nixon than giving Kissinger "negotiating assets". In early 1972, Nixon publicly revealed that Kissinger had secretly been negotiating with Tho since 1970 to prove that he was really committed to peace in Vietnam, despite what the antiwar movement had been saying about him for the last three years. Reflecting Kissinger's weakening hand in his talks with Tho, by 1971–72, Nixon had increasingly come to believe that the "linkage" concept of improving relations with the Soviet Union and China in exchange for those nations cutting off the supply of weapons to North Vietnam offered his best chance of a favorable peace deal. On 6 April 1972, Tho requested Kissinger to meet him in Paris, a request that Kissinger rejected as "insolent".
== In cancer progression and metastasis == Initiation of metastasis requires invasion, which is enabled by EMT. Carcinoma cells in a primary tumor lose cell-cell adhesion mediated by E-cadherin repression and break through the basement membrane with increased invasive properties, and enter the bloodstream through intravasation. Later, when these circulating tumor cells (CTCs) exit the bloodstream to form micro-metastases, they undergo MET for clonal outgrowth at these metastatic sites. Thus, EMT and MET form the initiation and completion of the invasion-metastasis cascade. At this new metastatic site, the tumor may undergo other processes to optimize growth. For example, EMT has been associated with PD-L1 expression, particularly in lung cancer. Increased levels of PD-L1 suppresses the immune system which allows the cancer to spread more easily. EMT confers resistance to oncogene-induced premature senescence. Twist1 and Twist2, as well as ZEB1 protects human cells and mouse embryonic fibroblasts from senescence. Similarly, TGF-β can promote tumor invasion and evasion of immune surveillance at advanced stages. When TGF-β acts on activated Ras-expressing mammary epithelial cells, EMT is favored and apoptosis is inhibited. This effect can be reversed by inducers of epithelial differentiation, such as GATA-3. EMT has been shown to be induced by androgen deprivation therapy in metastatic prostate cancer. Activation of EMT programs via inhibition of the androgen axis provides a mechanism by which tumor cells can adapt to promote disease recurrence and progression.
The Jesus and Mary Chain are a Scottish alternative rock band formed in East Kilbride in 1983. The band revolves around the songwriting partnership of brothers Jim and William Reid, who are the two founders and only consistent members of the band since its formation. They are recognized as key figures in the development of the noise pop and shoegaze subgenres. The band have had twelve top 40 entries and two top 10 hits in the UK Singles Chart in the course of their career. The Reid brothers recruited Douglas Hart on bass and Murray Dalglish on drums as their initial lineup. After signing to the independent label Creation Records, they released their first single "Upside Down" in 1984. Bobby Gillespie replaced Dalglish on drums, and their debut album, Psychocandy, was released to critical acclaim in 1985 on the major label WEA. After its release, Gillespie left the band to work on his own band Primal Scream. The band's biggest commercial success domestically was their second album Darklands, which reached No. 5 on the UK Albums Chart in 1987 and spawned the hit single "April Skies", peaking at No. 8 in the UK. The band released their third album, Automatic, in 1989, which spawned their first charting singles in the US, "Blues from a Gun" and "Head On", which were heavily played on alternative rock radio stations. Hart departed from the band two years later. The Jesus and Mary Chain then released the albums Honey's Dead in 1992 and Stoned & Dethroned in 1994, both of which continued their popularity in the US.
== See also == Reductive stress Glutathione synthetase deficiency Ophthalmic acid roGFP, a tool to measure the cellular glutathione redox potential Glutathione-ascorbate cycle Bacterial glutathione transferase Thioredoxin, a cysteine-containing small protein with very similar functions to reducing agents Glutaredoxin, an antioxidant protein that uses reduced glutathione as a cofactor and is reduced nonenzymatically by it Bacillithiol Mycothiol γ-L-Glutamyl-L-cysteine
Sources: en.wikipedia.org
=== Origins === Modern dentistry in Chengdu developed in the early 20th century through the work of Western medical missionaries. Ashley Woodward Lindsay, a graduate of the Royal College of Dental Surgeons of Ontario in Toronto, left Canada for Chengdu in 1907. With assistance from physician and missionary Omar L. Kilborn, Lindsay established a dental clinic on Sishengci Street. A history published through China's National Health Commission describes the clinic as marking the beginning of modern dentistry in Chengdu. Sichuan University dates the institutional history of the present hospital to the establishment of the Renji Dental Clinic in 1907. It records the expansion of the clinic into the Renji Dental Hospital in 1912. The hospital describes the 1912 institution as China's first specialized dental hospital. West China Union University, a missionary-founded university established in Chengdu in 1910, subsequently became the principal institutional base for Lindsay's dental work. In 1917, the university established its dental education program. The dental school at West China Union University was the earliest dental education institution in China. Several early faculty members were trained at the University of Toronto Faculty of Dentistry, which credits these dentists with helping introduce a university-based model of dental education to China and with contributing to the development of national dental-education standards. In the late 1920s the medical and dental programs of West China Union University were brought into a combined academic structure.
== History == Eli Lilly and Company first applied for a patent for a method of glycemic control using tirzepatide in 2016. After passing phase III clinical trials, Eli Lilly applied to the US Food and Drug Administration (FDA) for approval in 2021, with a priority review voucher. After completing the SURPASS-2 trial (NCT03987919), the company announced in April 2022 that tirzepatide had successfully met its clinical endpoints in obese and overweight participants without diabetes. In industry-funded preliminary trials, tirzepatide showed minor improvement of reductions (2.01%–2.30% depending on dosage) in glycated hemoglobin tests relative to the injected GLP-1 analog semaglutide (1.86%). A 10 mg dose has been shown to be effective in reducing insulin resistance, with a reduction of around 8% from baseline, measured using HOMA2-IR (computed with fasting insulin). Fasting levels of insulin-like growth factor (IGF) binding proteins such as IGFBP1 and IGFBP2 increased after tirzepatide treatment, increasing insulin sensitivity. A 2021 meta-analysis found that over 1 year of clinical use, tirzepatide was superior to dulaglutide, semaglutide, insulin degludec, and insulin glargine in improving blood sugar control and reducing body weight. In a phase III double-blind, randomized, controlled trial supported by Eli Lilly, nondiabetic adults with a body mass index of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, were randomized to receive once-weekly, subcutaneous tirzepatide (5, 10, or 15 mg) or placebo.
=== India === In NPCB survey (2001–2002) Corneal opacity was the 6th major cause of blindness in India, which accounts for 0.9% of total blind population. In the RAAB (Rapid Assessment of Avoidable Blindness) survey (2006–2007) Corneal opacity including Trachoma was mentioned as the second major cause of blindness, which accounts for 6.5% of total blindness.
Flattened squamous cells are more resistant to both abrasion and infection. The permeability of the epithelium allows for an effective response from the immune system since antibodies and other immune components can easily reach the surface. The vaginal epithelium differs from the similar tissue of the skin. The epidermis of the skin is relatively resistant to water because it contains high levels of lipids. The vaginal epithelium contains lower levels of lipids. This allows the passage of water and water-soluble substances through the tissue. Keratinization happens when the epithelium is exposed to the dry external atmosphere. In abnormal circumstances, such as in pelvic organ prolapse, the mucosa may be exposed to air, becoming dry and keratinized.
The human cornea has five layers (possibly six, if the Dua's layer is included). Corneas of other primates have five known layers. The corneas of cats, dogs, wolves, and other carnivores only have four. From the anterior to posterior the layers of the human cornea are:
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.